
Plozalizumab
CAS No. 1610761-46-0
Plozalizumab( —— )
Catalog No. M36823 CAS No. 1610761-46-0
Plozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 565 | Get Quote |
![]() ![]() |
5MG | 943 | Get Quote |
![]() ![]() |
10MG | 1492 | Get Quote |
![]() ![]() |
25MG | 2144 | Get Quote |
![]() ![]() |
50MG | 2898 | Get Quote |
![]() ![]() |
100MG | 3825 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NamePlozalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlozalizumab (MLN-1202) is a humanized, selective, and potent anti-CCR2 antibody with antitumor activity, used in the study of malignant melanoma.
-
DescriptionPlozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetCCR
-
RecptorCCR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1610761-46-0
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jahchan NS, et al. Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Front Immunol. 2019 Jul 25;10:1611.?
molnova catalog



related products
-
Leronlimab
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody with both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV, non-alcoholic steatohepatitis (NASH), and breast cancer.
-
CCR3 antagonist 1
CCR3 antagonist 1 is a potent CCR3 antagonist used in researching inflammatory and immunologic diseases.
-
Nazartinib
Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor.